Uceris from Salix Pharmaceuticals granted final FDA approval

RALEIGH, N.C. — Salix Pharmaceuticals on Thursday announced that the Food and Drug Administration granted final approval for the company's Uceris (budesonide) rectal foam for patients with mild-to-moderate distal ulcerative colitis. The foams is a corticosteroid administered rectally that combats treatment limitations associated with current therapies, which can be ineffective due to insufficient distribution of the active drug to the distal colon, the company stated. 

 

UC is a chronic disease affecting the large intestine (the colon) in which the lining of the colon becomes inflamed and develops open sores that produce mucous and pus. Distal UC is described by the company as either "inflammation localized to the rectum" or "inflammation localized to the distal colon and rectum."